Business Wire

NY-SONIC-ENTERPRISES

Share
World-Renowned and Globally Recognized Photographer Anne Geddes Brings Her Artistry and Creativity to NFTs for the First Time With Her Mother’s Day 2022 Collection

Anne Geddes , photographer globally renowned for her iconic imagery capturing the beauty, purity, and joy of new life, brings her artistry and creativity to NFTs for the first time. On May 6, 2022, the Anne Geddes Mother’s Day 2022 NFT Collection will drop at 9 a.m. PT, commemorating the holiday. The Collection contains nine selections made available in a variety of format configurations. Her highly anticipated collection will be sold exclusively through the certified carbon-neutral blockchain marketplace WAX and powered by the Shopify app Waxify . Her renowned artwork will be available for purchase in FIAT (USD) through credit card, PayPal and other traditional payments as well as WAXP, Bitcoin, and Ethereum. This crossover collection seamlessly bridges the gap between the mainstream Anne Geddes photography collectors and avid NFT collectors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005269/en/

Buyers can pre-register for the sale at annegeddes.io , with a pre-sale beginning a day prior — May 5, 2022, at 9 a.m. PT.

The configurations of the collection include:

Limited Edition Digital Prints:

All nine images in the Mother's Day collection are minted as digital art prints. Every digital print can be "redeemed" for a corresponding physical 8”x10” print.

Signature Series:

All nine images from the collection make up the “Signature Series.” Every digital print will feature an original authenticated digital signature and a signed physical print. Only 20 of each print will be available for a total of 180 prints. These prints are created exclusively for the Anne Geddes Mother’s Day 2022 NFT Collection.

1-of-1 Collection:

Two images from the collection will be available as limited edition one-of-one digital and physical prints. Each image will feature an authenticated original digital signature and a signed one-of-a-kind physical print.

Each artfully minted NFT will come with an exclusive redemption offering for a physical piece of art, made exclusively for this release. Every NFT will also contain a minted video of Anne personally discussing each of the images. Additionally, all digital and physical prints will be made exclusively for this release and will not be made again in this format.

Anne will also be auctioning off one elusive private shoot in her studio in New York to raise money for mothers and children in Ukraine. An additional commemorative NFT to support Ukrainian children will be available in the gallery to help raise additional funds. All proceeds will be provided to The American Red Cross.

While Anne’s photography has been treasured and respected by many generations, her evocative move into the blockchain with an iconic Anne Geddes Mother's Day NFT Collection is groundbreaking for an artist of this caliber.

Link:

ClickThru

Social Media:

https://www.facebook.com/annegeddes

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye